Information Provided By:
Fly News Breaks for March 22, 2019
VAR
Mar 22, 2019 | 07:20 EDT
Baird analyst Jason Bednar upgraded Varian Medical to Outperform from Neutral and raised his price target to $162 from $127. In a research note to investors, Bednar says that with near-term trends sounding healthy, multiple paths are emerging for Varian to sustain upper-single digit plus oncology order growth, and low- to mid-teens EPS growth looking increasingly likely and sustainable into fiscal 2020 and beyond, he believes Varian is quickly becoming a premium medech grower and a stock that investors can consider a core medtech holding.
News For VAR From the Last 2 Days
There are no results for your query VAR